Tango Therapeutics up on FDA nod for trial of cancer drug in humans

Tango Therapeutics

03/04/2023 15:40

** Shares of cancer drug developer Tango Therapeutics Inc
 TNGX.O  rise ~12% to $4.41   
    ** Co says the U.S. Food and Drug Administration (FDA) has
cleared the application to begin human trials for its
experimental drug to treat cancers caused by a certain type of
mutation  
    ** TNGX plans to begin an early-mid satge trial of the drug
candidate, TNG260, in the second half of 2023
    ** The trial will evaluate safety and efficacy of TNG260 in
combination with pembrolizumab in patients with locally advanced
solid tumors with STK11 loss-of-function mutation -TNGX    
    ** TNG260 is being tested to treat cancers caused by
mutations in the STK11 gene which codes for a protein
responsible for tumor suppression
    ** Stock down ~40% this year

 (Reporting by Mariam Sunny)
 ((Mariam.ESunny@thomsonreuters.com;))